Some genetic profiles indicate faster GLP-1 metabolism, necessitating higher maintenance doses
The company has published studies and works with researchers in the microbiome space
GLP-1s are still relatively new in the way theyre being used now, and we simply dont have enough data to understand their full impact over time especially in younger populations or those using them off-label
Additionally, research is ongoing to determine whether these drugs can also be used to treat drug addictions, Alzheimers, and Parkinsons diseases (Beckwith, 2023)
BDNF as a promising therapeutic agent in Parkinsons disease
Observable signs of degradation include discolouration, clumping, visible particulates, or a broken tamper-evident seal on the vial